Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review

Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review

Parisa Ghasemiyeh,1,2 Afshin Borhani-Haghighi,3 Iman Karimzadeh,1 Soliman Mohammadi-Samani,2,4 Afsaneh Vazin,1 Anahid Safari,5 Adnan I Qureshi6 1Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 2Pharmaceutical Sciences Research Center, School...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ghasemiyeh P, Borhani-Haghighi A, Karimzadeh I, Mohammadi-Samani S, Vazin A, Safari A, Qureshi AI
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
sars-cov-2
covid-19
stroke
potential drug-drug interactions
adverse drug reactions
pharmacokinetics.
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/f504207bee6845888e5142d0463359dd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f504207bee6845888e5142d0463359dd
record_format dspace
spelling oai:doaj.org-article:f504207bee6845888e5142d0463359dd2021-12-02T13:02:48ZMajor Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review1178-203Xhttps://doaj.org/article/f504207bee6845888e5142d0463359dd2020-06-01T00:00:00Zhttps://www.dovepress.com/major-neurologic-adverse-drug-reactions-potential-drugndashdrug-intera-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XParisa Ghasemiyeh,1,2 Afshin Borhani-Haghighi,3 Iman Karimzadeh,1 Soliman Mohammadi-Samani,2,4 Afsaneh Vazin,1 Anahid Safari,5 Adnan I Qureshi6 1Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 2Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 3Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 4Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 5Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 6Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO, USACorrespondence: Afshin Borhani-HaghighiClinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran+98-713-6281572Email neuro.ab@gmail.comAbstract: Stroke has been considered as one of the underlying diseases that increases the probability of severe infection and mortality. Meanwhile, there are ongoing reports of stroke subsequent to COVID-19 infection. In this narrative paper, we reviewed major neurologic adverse drug reactions (ADRs) and pharmacokinetics of drugs which are routinely used for COVID-19 infection and their potential drug–drug interactions (PDDIs) with common drugs used for the treatment of stroke. It is highly recommended to monitor patients on chloroquine (CQ), hydroxychloroquine (HCQ), antiviral drugs, and/or corticosteroids about initiation or progression of cardiac arrhythmias, delirium, seizure, myopathy, and/or neuropathy. In addition, PDDIs of anti-COVID-19 drugs with tissue plasminogen activator (tPA), anticoagulants, antiaggregants, statins, antihypertensive agents, and iodine-contrast agents should be considered. The most dangerous PDDIs were interaction of lopinavir/ritonavir or atazanavir with clopidogrel, prasugrel, and new oral anticoagulants (NOACs).Keywords: SARS-CoV-2, COVID-19, stroke, potential drug–drug interactions, adverse drug reactions, pharmacokineticsGhasemiyeh PBorhani-Haghighi AKarimzadeh IMohammadi-Samani SVazin ASafari AQureshi AIDove Medical Pressarticlesars-cov-2covid-19strokepotential drug-drug interactionsadverse drug reactionspharmacokinetics.Therapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 16, Pp 595-605 (2020)
institution DOAJ
collection DOAJ
language EN
topic sars-cov-2
covid-19
stroke
potential drug-drug interactions
adverse drug reactions
pharmacokinetics.
Therapeutics. Pharmacology
RM1-950
spellingShingle sars-cov-2
covid-19
stroke
potential drug-drug interactions
adverse drug reactions
pharmacokinetics.
Therapeutics. Pharmacology
RM1-950
Ghasemiyeh P
Borhani-Haghighi A
Karimzadeh I
Mohammadi-Samani S
Vazin A
Safari A
Qureshi AI
Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review
description Parisa Ghasemiyeh,1,2 Afshin Borhani-Haghighi,3 Iman Karimzadeh,1 Soliman Mohammadi-Samani,2,4 Afsaneh Vazin,1 Anahid Safari,5 Adnan I Qureshi6 1Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 2Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 3Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 4Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 5Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 6Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO, USACorrespondence: Afshin Borhani-HaghighiClinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran+98-713-6281572Email neuro.ab@gmail.comAbstract: Stroke has been considered as one of the underlying diseases that increases the probability of severe infection and mortality. Meanwhile, there are ongoing reports of stroke subsequent to COVID-19 infection. In this narrative paper, we reviewed major neurologic adverse drug reactions (ADRs) and pharmacokinetics of drugs which are routinely used for COVID-19 infection and their potential drug–drug interactions (PDDIs) with common drugs used for the treatment of stroke. It is highly recommended to monitor patients on chloroquine (CQ), hydroxychloroquine (HCQ), antiviral drugs, and/or corticosteroids about initiation or progression of cardiac arrhythmias, delirium, seizure, myopathy, and/or neuropathy. In addition, PDDIs of anti-COVID-19 drugs with tissue plasminogen activator (tPA), anticoagulants, antiaggregants, statins, antihypertensive agents, and iodine-contrast agents should be considered. The most dangerous PDDIs were interaction of lopinavir/ritonavir or atazanavir with clopidogrel, prasugrel, and new oral anticoagulants (NOACs).Keywords: SARS-CoV-2, COVID-19, stroke, potential drug–drug interactions, adverse drug reactions, pharmacokinetics
format article
author Ghasemiyeh P
Borhani-Haghighi A
Karimzadeh I
Mohammadi-Samani S
Vazin A
Safari A
Qureshi AI
author_facet Ghasemiyeh P
Borhani-Haghighi A
Karimzadeh I
Mohammadi-Samani S
Vazin A
Safari A
Qureshi AI
author_sort Ghasemiyeh P
title Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review
title_short Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review
title_full Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review
title_fullStr Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review
title_full_unstemmed Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review
title_sort major neurologic adverse drug reactions, potential drug–drug interactions and pharmacokinetic aspects of drugs used in covid-19 patients with stroke: a narrative review
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/f504207bee6845888e5142d0463359dd
work_keys_str_mv AT ghasemiyehp majorneurologicadversedrugreactionspotentialdrugndashdruginteractionsandpharmacokineticaspectsofdrugsusedincovid19patientswithstrokeanarrativereview
AT borhanihaghighia majorneurologicadversedrugreactionspotentialdrugndashdruginteractionsandpharmacokineticaspectsofdrugsusedincovid19patientswithstrokeanarrativereview
AT karimzadehi majorneurologicadversedrugreactionspotentialdrugndashdruginteractionsandpharmacokineticaspectsofdrugsusedincovid19patientswithstrokeanarrativereview
AT mohammadisamanis majorneurologicadversedrugreactionspotentialdrugndashdruginteractionsandpharmacokineticaspectsofdrugsusedincovid19patientswithstrokeanarrativereview
AT vazina majorneurologicadversedrugreactionspotentialdrugndashdruginteractionsandpharmacokineticaspectsofdrugsusedincovid19patientswithstrokeanarrativereview
AT safaria majorneurologicadversedrugreactionspotentialdrugndashdruginteractionsandpharmacokineticaspectsofdrugsusedincovid19patientswithstrokeanarrativereview
AT qureshiai majorneurologicadversedrugreactionspotentialdrugndashdruginteractionsandpharmacokineticaspectsofdrugsusedincovid19patientswithstrokeanarrativereview
_version_ 1718393542299090944

Ejemplares similares